Piramal Pharma Limited (PPL), demerged from Piramal Enterprises in 2022, enjoys high investment-grade credit ratings (e.g., CARE AA; Stable upgraded July 2025) under the issuer-pays model, which critics claim manufactures trust to enable cheap borrowing despite severe financial strain—Q2 FY26 revenue down ~9% to ₹2,044 crore, EBITDA crashed 44%, net loss ₹99 crore, high leverage (~3x net debt-to-EBITDA), weak interest coverage, and share price falling ~19% from ₹204 (July 2025) to ~₹166 (mid-January 2026). This rating resilience contrasts sharply with the alleged “Digwal massacre” at its Telangana plant: repeated effluent dumping (comprehensively reported by 2018) contaminating water/soil, devastating farmland, and linked to spikes in kidney failures, respiratory issues, and cancers among villagers; despite NGT’s ₹8.3 crore polluter-pays fine (2019), TSPCB closure orders, and weak enforcement, SEBI deemed events non-material post-demerger, reportedly shielded by Ajay Piramal’s substantial BJP donations and crony ties. Echoing the Piramal Finance rating controversy, PPL’s playbook—restructurings to quarantine liabilities, OTC pivot to mask industrial risks, and paid-for “stable” ratings—externalizes financial, environmental, and human costs onto investors and poisoned communities, highlighting the urgent need to dismantle the ratings oligopoly and opaque political funding that sustain such systemic expropriation.